Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirzepatide - Eli Lilly and Company

Next Previous
Drug Profile

Tirzepatide - Eli Lilly and Company

Alternative Names: GIP/GLP-1 RA; LY-3298176; Mounjaro; Mounjaro KwikPen; Zepbound; ZEPBOUND KwikPen

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Glucagon-like peptides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Sleep disorder therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus
  • Preregistration Heart failure
  • Phase III Plaque psoriasis; Psoriatic arthritis; Type 1 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 18 Sep 2025 Efficacy and adverse event data from the phase III SURPASS-PEDS trial in Type 2 diabetes mellitus released by Eli Lilly and Company
  • 31 Jul 2025 Efficacy and adverse events data from a phase III SURPASS-CVOT trial in Type 2 diabetes mellitus released by Eli Lilly and Company
  • 16 Jul 2025 Launched for Obesity in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top